Calliditas Therapeutics IPO Presentation Deck
June 2020, 38 slides
  1. Calliditas Therapeutics
  2. Related Decks
  3. IPO Presentation Decks
company overview june | Calliditas Therapeutics
disclaimers | Calliditas Therapeutics
offering summary | Calliditas Therapeutics
management team | Calliditas Therapeutics
| Calliditas Therapeutics
pipeline primary biliary pome | Calliditas Therapeutics
investment highlights | Calliditas Therapeutics
our lead indication nephropathy significant unmet medical need i | Calliditas Therapeutics
disease origin and progression predominant theory patches galactose deficient immune recognition a | Calliditas Therapeutics
targets the presumed origin of disease | Calliditas Therapeutics
strong product protection and product exclusivity for | Calliditas Therapeutics
confirmatory proof of concept observed in phase trial | Calliditas Therapeutics
was generally well tolerated in | Calliditas Therapeutics
no clinically meaningful changes in blood pressure and body weight during treatment | Calliditas Therapeutics
no clinically relevant change in during treatment | Calliditas Therapeutics
ongoing pivotal phase clinical trial designed to confirm phase results | Calliditas Therapeutics
phase trial design criteria | Calliditas Therapeutics
covid business impact | Calliditas Therapeutics
potential to be first approved treatment for | Calliditas Therapeutics
planned open label extension and chronic dosing trials | Calliditas Therapeutics
global commercialization strategy | Calliditas Therapeutics
in the significant unmet medical need with considerable cost to society | Calliditas Therapeutics
market landscape research | Calliditas Therapeutics
payor summary perception of | Calliditas Therapeutics
nephrologist mapping research | Calliditas Therapeutics
commercialization strategy and market opportunity in the | Calliditas Therapeutics
opportunity for disease modifying treatment of liver diseases | Calliditas Therapeutics
primary biliary cholangitis | Calliditas Therapeutics
hepatitis | Calliditas Therapeutics
rationale and next steps | Calliditas Therapeutics
anticipated milestones | Calliditas Therapeutics
investment highlights | Calliditas Therapeutics
appendix | Calliditas Therapeutics
proteinuria surrogate evaluation | Calliditas Therapeutics
consistent trends support selection of versus cro rewire | Calliditas Therapeutics
manufacturing | Calliditas Therapeutics
board of directors | Calliditas Therapeutics
clinical advisory board comprising world leading specialists | Calliditas Therapeutics
See More
Calliditas Therapeutics
IPO Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Liver
Clinical trial
Related decks
Arbutus Biopharma
Investor Presentation
May 2023
Arbutus Biopharma
Investor Presentation
March 2023
NeuroBo Pharmaceuticals
Investor Presentation
December 2023
Albireo Pharma
Results
October 2022
Arbutus Biopharma
Results
November 2022
Arbutus Biopharma
Investor Presentation
August 2023
Axcella Health
Results
September 2022
Hepion Pharmaceuticals
Results
October 2022
Arbutus Biopharma
Investor Presentation
May 2023
Arbutus Biopharma
Investor Presentation
March 2023
NeuroBo Pharmaceuticals
Investor Presentation
December 2023
Albireo Pharma
Results
October 2022
Arbutus Biopharma
Results
November 2022
Arbutus Biopharma
Investor Presentation
August 2023
Axcella Health
Results
September 2022
Hepion Pharmaceuticals
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights